DKK 135.6
(7.45%)
Year | EBITDA | EBITDA Growth |
---|---|---|
2023 | 2.31 Billion DKK | -20.25% |
2022 | 2.49 Billion DKK | -23.62% |
2021 | 3.59 Billion DKK | 29.54% |
2020 | 2.81 Billion DKK | -11.55% |
2019 | 3.18 Billion DKK | 32.85% |
2018 | 2.39 Billion DKK | 6.38% |
2017 | 2.29 Billion DKK | 6.32% |
2016 | 2.05 Billion DKK | 8.42% |
2015 | 1.97 Billion DKK | 16.63% |
2014 | 1.68 Billion DKK | 15.75% |
2013 | 1.44 Billion DKK | 50.98% |
2012 | 967 Million DKK | -49.5% |
2011 | 1.73 Billion DKK | -36.8% |
2010 | 3.03 Billion DKK | 563.02% |
2009 | 529 Million DKK | -35.81% |
2008 | 712 Million DKK | -15.24% |
2007 | 840 Million DKK | 624.14% |
2006 | 675 Million DKK | -90.59% |
2005 | 693 Million DKK | 4666.67% |
2004 | 1.02 Billion DKK | -105.7% |
2003 | 481 Million DKK | -94.96% |
2002 | 9.39 Billion DKK | 0.0% |
Year | EBITDA | EBITDA Growth |
---|---|---|
2024 Q2 | 700 Million DKK | -10.83% |
2024 Q1 | 781 Million DKK | 98.0% |
2023 Q2 | 627 Million DKK | 45.14% |
2023 Q4 | 556 Million DKK | -11.18% |
2023 Q3 | 626 Million DKK | -0.16% |
2023 FY | - DKK | -20.25% |
2023 Q1 | 432 Million DKK | -56.41% |
2022 Q4 | 991 Million DKK | 28.87% |
2022 Q2 | 775 Million DKK | 181.82% |
2022 FY | - DKK | -23.62% |
2022 Q3 | 769 Million DKK | -0.77% |
2022 Q1 | 275 Million DKK | -71.2% |
2021 FY | - DKK | 29.54% |
2021 Q1 | 1.05 Billion DKK | 33.21% |
2021 Q3 | 854 Million DKK | -3.39% |
2021 Q4 | 955 Million DKK | 11.83% |
2021 Q2 | 884 Million DKK | -16.21% |
2020 Q1 | 545 Million DKK | -31.01% |
2020 Q3 | 1.19 Billion DKK | 283.28% |
2020 Q4 | 792 Million DKK | -33.56% |
2020 Q2 | 311 Million DKK | -42.94% |
2020 FY | - DKK | -11.55% |
2019 Q4 | 790 Million DKK | -23.75% |
2019 Q3 | 1.03 Billion DKK | 45.1% |
2019 FY | - DKK | 32.85% |
2019 Q2 | 714 Million DKK | 6.41% |
2019 Q1 | 671 Million DKK | -4.82% |
2018 Q2 | 588 Million DKK | 12.64% |
2018 Q4 | 705 Million DKK | 17.11% |
2018 FY | - DKK | 6.38% |
2018 Q1 | 522 Million DKK | -22.67% |
2018 Q3 | 602 Million DKK | 2.38% |
2017 FY | - DKK | 6.32% |
2017 Q2 | 573 Million DKK | 28.48% |
2017 Q4 | 675 Million DKK | 16.78% |
2017 Q3 | 578 Million DKK | 0.87% |
2017 Q1 | 446 Million DKK | -28.3% |
2016 Q4 | 622 Million DKK | 19.85% |
2016 FY | - DKK | 8.42% |
2016 Q3 | 519 Million DKK | -3.35% |
2016 Q1 | 477 Million DKK | -18.18% |
2016 Q2 | 537 Million DKK | 12.58% |
2015 FY | - DKK | 16.63% |
2015 Q4 | 583 Million DKK | 13.87% |
2015 Q3 | 512 Million DKK | 13.02% |
2015 Q2 | 453 Million DKK | -1.31% |
2015 Q1 | 459 Million DKK | -0.65% |
2014 Q1 | 389 Million DKK | 13.08% |
2014 FY | - DKK | 15.75% |
2014 Q2 | 438 Million DKK | 12.6% |
2014 Q3 | 401 Million DKK | -8.45% |
2014 Q4 | 462 Million DKK | 15.21% |
2013 Q1 | 323 Million DKK | 104.43% |
2013 FY | - DKK | 50.98% |
2013 Q4 | 344 Million DKK | -22.87% |
2013 Q3 | 446 Million DKK | 28.53% |
2013 Q2 | 347 Million DKK | 7.43% |
2012 Q3 | 262 Million DKK | 18.02% |
2012 Q4 | 158 Million DKK | -39.69% |
2012 FY | - DKK | -49.5% |
2012 Q1 | 268 Million DKK | -75.25% |
2012 Q2 | 222 Million DKK | -17.16% |
2011 Q3 | 311 Million DKK | -1.58% |
2011 Q2 | 316 Million DKK | 54.15% |
2011 Q1 | 205 Million DKK | -40.23% |
2011 FY | - DKK | -36.8% |
2011 Q4 | 1.08 Billion DKK | 248.23% |
2010 Q1 | 192 Million DKK | 508.51% |
2010 FY | - DKK | 563.02% |
2010 Q4 | 343 Million DKK | -84.9% |
2010 Q3 | 2.27 Billion DKK | 913.84% |
2010 Q2 | 224 Million DKK | 16.67% |
2009 Q3 | 145 Million DKK | 26.09% |
2009 Q2 | 115 Million DKK | 144.68% |
2009 FY | - DKK | -35.81% |
2009 Q1 | 47 Million DKK | 0.0% |
2009 Q4 | -47 Million DKK | -132.41% |
2008 FY | - DKK | -15.24% |
2007 FY | - DKK | 624.14% |
2006 FY | - DKK | -90.59% |
2005 FY | - DKK | 4666.67% |
2004 FY | - DKK | -105.7% |
2003 FY | - DKK | -94.96% |
2002 FY | - DKK | 0.0% |
Name | EBITDA | EBITDA Difference |
---|---|---|
Ambu A/S | 691 Million DKK | -234.732% |
ChemoMetec A/S | 193.97 Million DKK | -1092.409% |
Demant A/S | 5.21 Billion DKK | 55.673% |
Scandinavian Medical Solutions A/S | 21.22 Million DKK | -10797.329% |
ViroGates A/S | -12.48 Million DKK | 18632.169% |